Measurement: 1.0 mg equals 6 units, 1.5 mg equals 9 units, and 2.0 mg equals 12 units
STEP 5 yielded very similar results (15.2% vs
It is only given under medical supervision and the dosage should be carefully monitored by a healthcare professional
Researched applications In the published preclinical and clinical literature the effects of Cagrilintide are documented in the following areas: Obesity (stand-alone) , Phase 2 data (Lau 2021, 10.8 % at 4.5 mg) Obesity + Semaglutide (CagriSema) , Phase 3 REDEFINE 1 (25.3 %) T2DM + obesity , Phase 3 REDEFINE 2 Cardiovascular prevention , Phase 3 REDEFINE 3 (n ~ 7000) MASLD/MASH , exploratory in Phase 2 Type 2 diabetes (monotherapy) , preclinical data Prediabetes , exploratory plans Science & studies 4.1 Key publications Lau D.C.W., Erichsen L., Francisco A.M., et al
Next, our team performs comprehensive quality testing to verify purity and consistency